Teva Pharmaceutical Industries Ltd banner

Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 9 370 ILS -0.84% Market Closed
Market Cap: ₪105.5B

EV/EBITDA

8.8
Current
32%
More Expensive
vs 3-y average of 6.7

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
8.8
=
Enterprise Value
₪154.1B
/
EBITDA
$5.1B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
8.8
=
Enterprise Value
₪154.1B
/
EBITDA
$5.1B

Valuation Scenarios

Teva Pharmaceutical Industries Ltd is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (6.7), the stock would be worth ₪7 102 (24% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-62%
Maximum Upside
+43%
Average Downside
18%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 8.8 ₪9 370
0%
3-Year Average 6.7 ₪7 102
-24%
5-Year Average 6.4 ₪6 813.09
-27%
Industry Average 3.3 ₪3 551.47
-62%
Country Average 12.7 ₪13 438.5
+43%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
₪154.1B
/
Jan 2026
$5.1B
=
8.8
Current
₪154.1B
/
Dec 2026
$5.2B
=
29.8
Forward
₪154.1B
/
Dec 2027
$5.6B
=
27.4
Forward
₪154.1B
/
Dec 2028
$6B
=
25.7
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
IL
Teva Pharmaceutical Industries Ltd
TASE:TEVA
106.4B ILS 8.8 24.1
US
Eli Lilly and Co
NYSE:LLY
869.1B USD 28.5 42.1
US
Johnson & Johnson
NYSE:JNJ
555.5B USD 16.9 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.7 19.8
UK
AstraZeneca PLC
LSE:AZN
231.9B GBP 16.6 30
US
Merck & Co Inc
NYSE:MRK
289.8B USD 9.9 15.9
CH
Novartis AG
SIX:NOVN
228B CHF 12.5 20.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 8.2 11.2
US
Pfizer Inc
NYSE:PFE
156.5B USD 7.7 20.1
US
Bristol-Myers Squibb Co
NYSE:BMY
119B USD 7.1 16.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Average EV/EBITDA: 46.8
8.8
5%
1.8
US
Eli Lilly and Co
NYSE:LLY
28.5
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.9
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.7
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.6
12%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
4%
2.5
CH
Novartis AG
SIX:NOVN
12.5
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.2
2%
4.1
US
Pfizer Inc
NYSE:PFE
7.7
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
P/E Multiple
Earnings Growth PEG
IL
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Average P/E: 22.7
24.1
-70%
N/A
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.8
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30
25%
1.2
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
CH
Novartis AG
SIX:NOVN
20.3
14%
1.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
0%
N/A
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1

Market Distribution

In line with most companies in Israel
Percentile
37th
Based on 409 companies
37th percentile
8.8
Low
0 — 7.2
Typical Range
7.2 — 21.8
High
21.8 —
Distribution Statistics
Israel
Min 0
30th Percentile 7.2
Median 12.7
70th Percentile 21.8
Max 361.2

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
4 992.69 ILS
Overvaluation 47%
Intrinsic Value
Price ₪9 370
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett